The one-point increase suggests a nearly static payment environment in life sciences and medtech; while technically positive, the change is so small that factors such as sample selection are likely to be influential. Suppliers looking to improve cash flow should use a late payment calculator to see the impacts of late payments.
One-line summary: Payment performance in Life Sciences & Medtech improved from 59.8 (118 companies) in 2023 to 60.8 (113 companies) in 2024.